Literature DB >> 20930391

Preparation and characterization of laminin-derived peptide AG73-coated liposomes as a selective gene delivery tool.

Yoichi Negishi1, Daiki Omata, Hiroshi Iijima, Nobuhito Hamano, Yoko Endo-Takahashi, Motoyoshi Nomizu, Yukihiko Aramaki.   

Abstract

Targeted gene delivery to cancer cells is considered as a promising strategy for cancer therapy. Since, several targeting ligands have been studied for cancer gene therapy, such as transferrin, folate, anisamide, RGD-peptide, and antibodies. We have focused on AG73 peptide, which is derived from the globular domain of the laminin α1 chain. AG73 peptide is known as a ligand for syndecans, one of the major heparin sulfate-containing transmembrane proteoglycans. Syndecan-2 is highly expressed in various cancer cells and plays a role in angiogenesis. In this study, we prepared AG73-labeled polyethyleneglycol-modified liposomes (AG73-PEG liposomes) for gene delivery tool to syndecan-2 overexpressing cancer cells, and assessed the characterization of AG73-PEG liposomes. We confirmed the conjugation of AG73 peptide to PEG liposomes by reverse-phase high-performance liquid chromatography analysis. Electron microscopy analysis showed that monodiseperse AG73-labeled lipsomes were prepared. We also assessed the gene transfection efficiency of AG73-PEG liposomes in syndecan-2 overexpressing cancer cells or syndecan-2 less expressing cancer cells. As a result, AG73-mediated liposomal gene transfection efficiency was increased by 100-fold in syndecan-2 overexpressing cancer cells compared to syndecan-2 less expressing cancer cells. These results suggested that AG73-PEG liposomes were successfully prepared from a point of view of the modification of AG73 peptide to PEG-liposomes and the particle size of liposomes, which presented nano size. Furthermore, our results suggest that AG73-PEG liposomes can be a useful targeted gene delivery vehicle for syndecan-2 overexpressing cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930391     DOI: 10.1248/bpb.33.1766

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  Engineering liposomal nanoparticles for targeted gene therapy.

Authors:  C Zylberberg; K Gaskill; S Pasley; S Matosevic
Journal:  Gene Ther       Date:  2017-05-15       Impact factor: 5.250

2.  Screening a chemically defined extracellular matrix mimetic substrate library to identify substrates that enhance substrate-mediated transfection.

Authors:  Andrew Hamann; Alvin K Thomas; Tyler Kozisek; Eric Farris; Steffen Lück; Yixin Zhang; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-17

3.  Delivery of an angiogenic gene into ischemic muscle by novel bubble liposomes followed by ultrasound exposure.

Authors:  Yoichi Negishi; Keiko Matsuo; Yoko Endo-Takahashi; Kentaro Suzuki; Yuuki Matsuki; Norio Takagi; Ryo Suzuki; Kazuo Maruyama; Yukihiko Aramaki
Journal:  Pharm Res       Date:  2010-10-08       Impact factor: 4.200

4.  Local gene delivery system by bubble liposomes and ultrasound exposure into joint synovium.

Authors:  Yoichi Negishi; Yuka Tsunoda; Yoko Endo-Takahashi; Yusuke Oda; Ryo Suzuki; Kazuo Maruyama; Matsuo Yamamoto; Yukihiko Aramaki
Journal:  J Drug Deliv       Date:  2011-04-28

Review 5.  Laminin-111-derived peptides and cancer.

Authors:  Yamato Kikkawa; Kentaro Hozumi; Fumihiko Katagiri; Motoyoshi Nomizu; Hynda K Kleinman; Jennifer E Koblinski
Journal:  Cell Adh Migr       Date:  2012-12-21       Impact factor: 3.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.